+86-0755-3337-2138/2139
info@senovatech.com
Home
About
Product
Service
News
Join
Contact

Cn
Cn

Home

About

Product

APIs

Anti-Viral

Anti-Infection

Anti-Bacteria

Anti-Coagulants

Anti-Cancer

Advance Intermediates

Advance Intermediates

Peptides

Peptides

Fine Chemicals

Fine Chemicals

Others

Others

Service

News

Company news

Industry news

Company statement

Join

Contact

LNK

TOP
WE USE COOKIES ON OUR WEBSITE
This website uses Cookies to help improve your user experience.
MAYBE LATER
look over
I AGREE
/ Home / Product Center / Advance Intermediates / Anti-Cancer /

Trametinib Intermediate

APIs
Anti-Diabetes & Weight Loss Anti-Cancer Series Anti-Virus Series Others

Advance Intermediates
Anti-Diabetes Anti-Cancer Anti-Virus Anti-inflammatory Anti-Psychotic Cardiovascular Diseases Others

Peptides & Amino Acid
Peptides Pharmaceutical Grade Amino Acid Food/Feed Grade Amino Acid

Others
Others
N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,7,8-tetrahydropyrido[2,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide DMSO solvate
CAS
1187431-43-1
MF
C28H29FIN5O5S
MW
693.53
Purity
98%

Contact us
Indication
Trametinib Intermediate
Description

n May 2013, the US FDA approved trametinib (also referred to as GSK1120212 and JTP-74057), for the treatment of patients with unresectable or metastatic melanoma with BRAFV600e or BRAFV600K mutations as detected by an FDA-approved test